H.C. Wainwright Sticks to Its Buy Rating for Eleven Biotherapeutics

By Carrie Williams

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Eleven Biotherapeutics (NASDAQ: EBIO) today and set a price target of $2. The company’s shares closed yesterday at $1.47.

According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 1.7% and a 33.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.

Eleven Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.

The company has a one-year high of $2.01 and a one-year low of $0.62. Currently, Eleven Biotherapeutics has an average volume of 1.54M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Eleven Biotherapeutics, Inc. is a preclinical stage biopharmaceutical company, which engages in medical development. It involves in the management of proprietary protein engineering platform called AMP-Rx for the development and discovery of protein therapeutics to treat diseases of the eye.